Sara P. Garcia

机构：Eli Lilly (United States), Verve Therapeutics (United States) · ORCID：0000-0003-3312-6454

发表论文 104 篇 · 总被引 7003 次 · h-index 29

代表论文

• BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis (2015 · Nature · 被引 935)
• In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates (2021 · Nature · 被引 808)
• Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors (2019 · Nature · 被引 706)
• CRISPR C-to-G base editors for inducing targeted DNA transversions in human cells (2020 · Nature Biotechnology · 被引 602)
• High levels of AAV vector integration into CRISPR-induced DNA breaks (2019 · Nature Communications · 被引 454)
• Assessment of computational methods for the analysis of single-cell ATAC-seq data (2019 · Genome biology · 被引 417)